Статья
СИМПАТИЧЕСКАЯ ДЕНЕРВАЦИЯ ПОЧЕЧНЫХ АРТЕРИЙ: ПРОШЛОЕ, НАСТОЯЩЕЕ, БУДУЩЕЕ
Представлен анализ современных исследований, показывающих эффективность процедуры симпатической ренальной денервации у больных с артериальной гипертензией. Обозначены перспективы использования данного метода, в том числе и у больных сахарным диабетом, легочной гипертензией и нарушениями ритма сердца.
1. Timofeeva TN, Deev AD, Shalnova SA, et al. Analytic certificate on arterial hypertension epidemiology in 2008 and its changes from 2003 to 2008 according to three monitor studies. Moscow: Ministry of Public Health and Social Development of Russian Federation; 2009. р.3. Russian (Тимофеева Т.Н., Деев А.Д., Шальнова С.А. и др. Аналитическая справка об эпидемиологической ситуации по АГ в 2008 году и ее динамике с 2003 по 2008 год по трем проведенным мониторингам. М.: Министерство здравоохранения и социального развития Российской Федерации; 2009. с. 3).
2. Stokes J, Kannel W, Wolf P, et al. Blood pressure as risk factor for cardiovascular disease. The Framingham Study — 30 years of follow-up. Hypertension 1989; 13(Suppl.1): 13-8.
3. Shalnova SA, Deev AD, Oganov RG. Factors affecting cardiovascular mortality in Russian population. Cardiovascular Therapy and Prevention 2005; 4(1): 4-9. Russian (Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика 2005; 4(1): 4-9).
4. Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease 2001. Lancet 2008; 371(9623): 1513-8.
5. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217-23.
6. Erdine S, Ari O, Zanchetti A, et al. ESH-ESC guidelines for the management of hypertension. Herz 2006; 31(4): 331-8.
7. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertension 2007; 25(6): 1105-87.
8. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Hypertension 2009; 27(11): 2121-58.
9. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52(5): 818-27.
10. Falaschetti E, Chaudhury M, Mindell J, et al. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009; 53(3): 480-6.
11. Howes F, Hansen E, Williams D, et al. Barriers to diagnosing and managing hypertension — a qualitative study in Australian general practice. Aust Fam Physician 2010; 39(6): 511-6.
12. Howes F, Hansen E, Nelson M. Management of hypertension in general practice — a qualitative needs assessment of Australian. Gps Aust Fam Physician 2012; 41(5): 317-23.
13. Drexel T, Stefan C, et al. Renal denervation. Anadolu Kardiyol Derg 2014; 14(0): doi:10.5152/akd.2014.5294.
14. Эссенциальная артериальная гипертензия (гипертоническая болезнь). http://www.cardio-portal.ru/giperten/essen.html.
15. Medtronic Releases Results of SYMPLICITY HTN-3. http://phoenix.corporate-ir.net/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1913401&highlight= (March 29, 2014).
16. Esler MD, Krum H, Sobotka PA. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903-09.
17. Krum H, Barman N, Schlaich M, et al. Symplicity HTN-1 Study. Hypertension 2011; 57: 911-7.
18. Bhatt DL, Kandzari DE, O’Neill WW, et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. N Engl J Med 2014; 370: 1393-401.
19. PRNewswire — Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented today at the Transcatheter Cardiovascular Therapeutics: TCT Conference in San Francisco, Oct 28, 2013.
20. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Inves 1985; 75: 809-17.
21. Briganti EM, Shaw JE, Chadban SJ, et al. Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 179(3): 135-9.
22. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes melitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-101.
23. Jamerson КA, Julius S, Gudbradson T, et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1999; 17: 1153-60.
24. Masuo K, Mikami H, Ogihara T, et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young non obese Japanese population. Am J Hypertens 1997; 10: 77-83.
25. Grassi G, Dell’Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-65.
26. Grassi G, Dell’Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363-9.
27. Mahfoud F., Schlaich M., Kindermann I. et al. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study. Circulation 2011; 123: 1940-6.
28. Ukena C, Mahfoud F, Linz D, et al. Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias. EuroIntervention 2013; 9: 110-6.
29. Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-1170.
30. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-9.
31. Cuspidi C, Sala C, Negri F, et al. Prevalence of left ventricular hypertrophy in ypertension: an updated review of echocardiographic studies. Hum Hypertens 2012; 26(6): 343-9.
32. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-65.
33. Chen SL, Zhang FF, Xu J, et al. Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man pad-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). J Am Coll Cardiol 2013; 62: 1092-100.